IGF-1 LR3
Growth factor · By Preptide Pro editorial team · Last updated
IGF-1 LR3 is a growth factor peptide, and it is not FDA-approved. A modified, longer-acting analogue of insulin-like growth factor 1. It is used mainly as a cell-culture reagent and has little human research.
Not FDA-approvedChemistry (PubChem)
No matching PubChem compound record was found under this name.
Is IGF-1 LR3 FDA-approved?
Not FDA-approved. No matching NDA or BLA was found in openFDA (Drugs@FDA).
How much research is there on IGF-1 LR3?
PubMed lists 32 records for “"IGF-1 LR3" OR "LR3-IGF-I"”, of which 0 are tagged as human clinical trials.
| Recent study | Journal | Date |
|---|---|---|
| The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. | Front Endocrinol (Lausanne) | 2026 |
| Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration. | Int J Biol Macromol | 2025 Nov |
| IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep. | Am J Physiol Endocrinol Metab | 2025 Jan 1 |
| Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice. | J Alzheimers Dis | 2025 Jan |
| Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris. | Appl Microbiol Biotechnol | 2023 Jul |
Sources
This is general research information, not medical advice. Check with a clinician before using any compound.